SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

2 marketing jobs

Lundbeck logo
7 weeks ago

Vice President Marketing, Movement Disorders

Lundbeck

Deerfield, IL (Remote)Full time$320K/yr – $370K/yr
Lundbeck logo
7 weeks ago

Senior Director, Rare Epilepsy HCP & Payer Marketing

Lundbeck

Deerfield, IL (Remote)Full time$280K/yr – $315K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

2 jobs
Lundbeck logo

Vice President Marketing, Movement Disorders

Lundbeck

Deerfield, IL (Remote)

$320K/yr - $370K/yrIn-houseFull-timeSenior level12+ years exp.
7 weeks ago
Lundbeck logo

Senior Director, Rare Epilepsy HCP & Payer Marketing

Lundbeck

Deerfield, IL (Remote)

$280K/yr - $315K/yrIn-houseFull-timeSenior level
7 weeks ago
Lundbeck logo
Lundbeck

Vice President Marketing, Movement Disorders

Deerfield, IL (Remote)

$320K/yr – $370K/yrSenior Level12+ years expFull time

Posted 7 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the US amlenetug launch and commercialization, aligning cross-functional teams to shape disease-state education, omnichannel engagement, and market access in a rare-neurology setting.

  • Growth & Execution: Own launch readiness, lifecycle planning, and customer engagement strategies for patients, caregivers, payers, and HCPs.
  • Cross-Functional Leadership: Align brand positioning, messaging, and business goals with Medical Affairs, Market Access, Sales, Advocacy, and Analytics to drive sustainable performance.

Job Description

Responsibilities

  • Lead the development and execution of the US amlenetug marketing vision and commercialization strategy in partnership with the BU Head and key cross-functional leaders.
  • Drive launch readiness, disease-state market shaping, brand performance, lifecycle planning, and customer engagement strategies for amlenetug.
  • Ensure alignment of brand positioning, segmentation, messaging, and business objectives across the organization.
  • Develop patient, caregiver, payer, and HCP-centered strategies that improve diagnosis, treatment, and customer experience for individuals living with MSA.
  • Oversee integrated go-to-market planning, disease-state education, omnichannel engagement, and field readiness initiatives.
  • Leverage market insights, analytics, and competitive intelligence to optimize strategy, execution, and business performance.
  • Partner closely with Medical Affairs, Patient Services, Market Access, Sales, Advocacy, and Analytics to shape the MSA treatment ecosystem and support successful commercialization.
  • Build strong relationships with key opinion leaders (KOLs), advocacy organizations, movement disorder specialists, academic medical centers, and Centers of Excellence (COEs).
  • Represent the commercial organization at internal leadership meetings, field meetings, advisory boards, and relevant industry engagements, as appropriate.
  • Build and maintain a high-performing commercial culture focused on purpose-driven executional excellence and sustainable business performance.
Lundbeck logo

Lundbeck

3.9 Glassdoor

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com

Founded in 1915
Copenhagen, Capital Region of Denmark, DNK
6K employees (207 in marketing)
www.lundbeck.com
73% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
137.6K
Traffic Source Mix
Search
55.2%
Direct
34.1%
Referral
7.3%
Social
2.2%
Paid
1.1%

Headcount Trend

Current headcount: ~6K

Marketing Team

Marketing Team Size
207 (3% of company)
Median Career Experience
17 years
Median Tenure
2.8 years
Marketing Roles Posted (Last 30 Days)
3

People

Founders / CEO

Michelle Ll. Estonilo
Michelle Ll. Estonilo
Women’s Employee Resource Group Founder
At the company for 11 years

HR / Recruitment

Cassie Wu
Cassie Wu
Head of Global Talent Acquisition
At the company for 4 years 7 months
Greg Kozlowski
Greg Kozlowski
Director, Talent Acquisition - Head of US Talent Acquisition
At the company for 14 years 4 months

Marketing Leadership

Elizabeth L Schwartz
Elizabeth L Schwartz
VP, Head of US Neurology Marketing
At the company for 11 months
Cassie Wu
Cassie Wu
Head of Global Talent Acquisition
At the company for 4 years 7 months
Greg Kozlowski
Greg Kozlowski
Director, Talent Acquisition - Head of US Talent Acquisition
At the company for 14 years 4 months
Kelly Wang
Kelly Wang
Head of HR, Communications & Sustainability, China
At the company for 7 years 4 months

Funding

Total Funding
$564.1M
Last Raise
$564.1M
Post IPO Debt, 10 months ago

Funding History

  • May 2025
    Post IPO Debt • $564.1M
  • Mar 2020
    Grant

Recent News

Is H. Lundbeck A S (LDBB) stock undervalued historically - Trade Volume Report & Free Weekly Chart Analysis and Trade Guides
Oct 31, 2025 • newser.com
Lundbeck Announces Adoption Of ChatGPT Enterprise; To Integrate AI Into Daily Workflows
Oct 27, 2025 • Nasdaq
How supply shortages influence H. Lundbeck A S (LDBB) stock - Jobs Report & Weekly Momentum Stock Picks
Oct 21, 2025 • newser.com
Lundbeck and Contera partner for oligonucleotide-based medicines
Oct 21, 2025 • Yahoo
Chinese breakthrough status for Lundbeck’s bexicaserin
Oct 13, 2025 • The Pharma Letter
Lundbeck CEO wants EU countries to allocate fixed share of GDP to new medicines
Oct 8, 2025 • medwatch.com
Assessing Lundbeck Stock After Strong Three Year Rally and Steady Pharma Growth in 2025
Sep 24, 2025 • Yahoo Finance
Is Lundbeck Still Attractive After 12.6% Monthly Surge and Positive Neurology Pipeline Updates?
Sep 23, 2025 • simplywall.st
FDA rejects Lundbeck's application for PTSD drug
Sep 22, 2025 • medwatch.com
FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data
Sep 22, 2025 • Fierce Pharma
FDA slaps CRL on Otsuka and Lundbeck’s Rexulti sNDA
Sep 22, 2025 • Pharma Letter
FDA Rejects Lundbeck's Application for PTSD Drug
Sep 22, 2025 • MarketScreener
Avalo Therapeutics Appoints Kevin R. Lind To Board
Sep 22, 2025 • citybiz
Siding with adcom, FDA declines to approve Otsuka, Lundbeck's PTSD candidate
Sep 21, 2025 • FirstWord Pharma
Otsuka and Lundbeck receive complete response letter from U.S. FDA for sNDA of Rexulti (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sep 20, 2025 • MarketScreener
Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sep 20, 2025 • News Powered by Cision
Otsuka And Lundbeck Receive Complete Response Letter From U.S. FDA For SNDA Of Rexulti® (Brexpiprazole) In Combination With Sertraline For The Treatment Of Adults With PTSD
Sep 20, 2025 • Reuters
Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD
Sep 20, 2025 • Reuters
Investment bank confirms positive view of Lundbeck after meeting with management
Sep 16, 2025 • medwatch.com
GLP-1s claim the longevity stage at ARDD
Sep 15, 2025 • Longevity.Technology - Latest News, Opinions, Analysis and Research
Lundbeck offloads 27 markets to triple-partner alliance in bold growth gambit
Sep 11, 2025 • BioXconomy
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Sep 11, 2025 • prnasia.com
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Sep 11, 2025 • News Powered by Cision
Lundbeck unveils migraine data for eptinezumab at international congress
Sep 11, 2025 • Pharma Times
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Sep 11, 2025 • PharmiWeb
Lundbeck seeks to give rivals a headache with Vyepti data
Sep 11, 2025 • Pharma Letter
Fierce Pharma Asia—Crackdown on China licensing deals?; Daiichi, Merck's ADC win; Sun's import ban
Sep 11, 2025 • FiercePharma
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Sep 11, 2025 • PR Newswire UK
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
Sep 11, 2025 • Morningstar.com
Here are the 27 markets affected by Lundbeck's reorganization
Sep 10, 2025 • medwatch.com
LUNDBECK SELECTS SWIXX AS A KEY PARTNER IN A TRANSFORMATIVE MULTI-REGIONAL DEAL
Sep 10, 2025 • PR Newswire
Lundbeck CEO Looks To The Future With Sharper Commercial Focus
Sep 10, 2025 • Citeline News & Insights
Lundbeck hands over operations in 27 markets to partners in major shake-up
Sep 10, 2025 • Pharma Letter
LUNDBECK SELECTS SWIXX AS A KEY PARTNER IN A TRANSFORMATIVE MULTI-REGIONAL DEAL
Sep 10, 2025 • Morningstar.com
LUNDBECK SELECTS SWIXX AS A KEY PARTNER IN A TRANSFORMATIVE MULTI-REGIONAL DEAL
Sep 10, 2025 • PR Newswire UK
Lundbeck closes commercial departments: Enters into partnerships for 27 markets
Sep 9, 2025 • medwatch.com
Over 600 jobs impacted as Lundbeck tightens global focus
Sep 9, 2025 • FirstWord Pharma
Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers
Sep 9, 2025 • Fierce Pharma
Lundbeck retreats from dozens of markets, slashing staff
Sep 9, 2025 • pharmaphorum
Lundbeck to transfer commercial drugs to three partners in 27 markets
Sep 9, 2025 • Endpoints News
Lundbeck’s Bexicaserin: Promising Epilepsy Therapy Showing Strong Seizure Reduction
Aug 27, 2025 • PharmiWeb
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Aug 26, 2025 • PharmiWeb
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Aug 26, 2025 • BioSpace
Lundbeck to present new data on acquired epilepsy drug soon
Aug 25, 2025 • medwatch.com
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
Aug 25, 2025 • News Powered by Cision
Addiction Treatment Market to Reach USD 19.8 Billion by 2035, Driven by Rising Substance Abuse Cases Worldwide
Aug 22, 2025 • EIN Presswire
United States Epilepsy Drugs Market Report 2025 | $3.45 Bn Therapeutic Landscape & Forecasts to 2033 - Second-Generation Drugs Fuel Growth Amid Rising Prevalence - ResearchAndMarkets.com
Aug 21, 2025 • Business Wire
Migraine Treatment Market Outlook 2025–2035 | Trends, Dynamics, and North America Insights
Aug 21, 2025 • PharmiWeb
The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 16, 2025 • simplywall.st
Lundbeck dials up migraine drug's US peak sales estimate, stays positive on Rexulti's PTSD use
Aug 15, 2025 • FiercePharma
Lundbeck Korea recognized for flexible, family-friendly workplace with 4 GPTW awards
Aug 14, 2025 • koreabiomed.com
Lundbeck H1 2025 slides: Raises guidance as strategic brands drive 14% revenue growth
Aug 14, 2025 • Investing.com
Lundbeck is in the process of its largest capital restructuring: “I want to avoid the word ‘cuts’”
Aug 14, 2025 • medwatch.com
Denmark Pharmaceutical Market Research Report 2025-2033 | High R&D Investment, Academic-Healthcare Collaboration, and Supportive Regulations Fuel Expansion - ResearchAndMarkets.com
Aug 14, 2025 • Business Wire
6 Companies Hiring in Texas
Aug 14, 2025 • BioSpace
Lundbeck Raises Full-Year Outlook After Strong First Half
Aug 14, 2025 • MarketScreener
Lundbeck raises financial guidance for 2025
Aug 13, 2025 • TradingView
Lundbeck raises earnings forecast after strong first half
Aug 13, 2025 • medwatch.com
Guidance raised based on solid H1 results and continued strong expectations for the full year 2025
Aug 13, 2025 • News Powered by Cision
Lundbeck raises financial guidance for 2025
Aug 13, 2025 • News Powered by Cision
Research director on a changed Lundbeck: "We are no more than six years old"
Aug 4, 2025 • medwatch.com
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
Jul 28, 2025 • PR Newswire UK
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
Jul 28, 2025 • PR Newswire
11 Companies Hiring in California
Jul 23, 2025 • BioSpace
Lennox Gastaut Syndrome Market Research Report 2025-2035 | Regulatory Agencies Streamline Approval for Cutting-Edge Therapies, Pharmaceuticals Advance Novel AEDs
Jul 22, 2025 • Research and Markets
Otsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD
Jul 21, 2025 • BioSpace
Recon: FDA panel votes against Otsuka, Lundbeck PTSD drug; Biogen announces $2B upgrades to NC facilities
Jul 21, 2025 • Regulatory Affairs Professionals Society | RAPS
US FDA advisers recommend against Otsuka, Lundbeck's PTSD combination treatment
Jul 21, 2025 • MarketScreener
FDA Panel Rejects Efficacy of Rexulti for PTSD Treatment
Jul 21, 2025 • MarketScreener
Agitation in Alzheimer's Disease Research Report 2025-2035 | Market Expands with Shift Toward Targeted Therapies, Holistic Care Models, and Non-Pharmacological Interventions
Jul 21, 2025 • Research and Markets
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)
Jul 21, 2025 • PharmiWeb
Bipolar Disorder Market Research Report 2025-2035 | Pharma Leaders Advance Bipolar Disorder Treatment with Targeted Therapies and Genomic Innovation
Jul 21, 2025 • Research and Markets
Otsuka, Lundbeck’s PTSD Drug Fails to Win US FDA Panel Support
Jul 18, 2025 • Bloomberg.com
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)
Jul 18, 2025 • News Powered by Cision
US FDA advisers recommend against Otsuka's PTSD combination treatment
Jul 18, 2025 • MarketScreener
Otsuka, Lundbeck’s PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy
Jul 17, 2025 • BioSpace
Alcohol Use Disorder Market Analysis and Forecasts Report 2025-2035 | Targeted Therapies, Rising Awareness, and Expanding Clinical Pipeline - ResearchAndMarkets.com
Jul 16, 2025 • Business Wire
Europe Pharmaceutical Drugs Market Expands with R&D Innovation, Biologics Growth, and Regulatory Harmonization 2025–2032
Jul 10, 2025 • EIN Presswire
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
Jul 9, 2025 • GlobeNewswire News Room
2025 Lundbeck External Innovation Event: Co-creating the future of brain health
Jul 8, 2025 • Massachusetts Biotechnology Council
Alzheimer’s Drugs Market to witness 20% CAGR due to increased diagnosis and drug innovation by 2029
Jul 7, 2025 • PharmiWeb
Novo’s Wegovy retakes top TV spending spot in June, edging out AbbVie, J&J immunology ads
Jul 7, 2025 • FiercePharma
Leading Factor Driving the Bradykinesia Market in 2025: Rising Neurological Disorders Fueling The Growth
Jul 4, 2025 • EIN Presswire
Tardive Dyskinesia Therapeutics Market Report For M&A, Expansion, And Competitive Benchmarking (2025–2034)
Jul 3, 2025 • EIN Presswire
Data-driven visibility for the patient journey
Jul 2, 2025 • informaconnect.com
Lundbeck initiated with neutral view at BNP Paribas Exane, here's why
Jul 1, 2025 • thefly.com
Schizophrenia Drugs Market to Hit USD 12.78 Billion by 2032, Driven by Advancements in Atypical Antipsychotics and Injectable Formulations – SNS Insider
Jun 26, 2025 • SNS Insider pvt ltd
Regulatory actions for June 25, 2025
Jun 25, 2025 • BioWorld Financial Watch
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Jun 24, 2025 • News Powered by Cision
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
Jun 24, 2025 • PharmiWeb
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of congenital adrenal hyperplasia
Jun 24, 2025 • PharmiWeb
FDA, EMA Grant Orphan Drug Designation To Lundbeck's Lu Ag13909
Jun 24, 2025 • Reuters
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Jun 24, 2025 • Reuters
Lundbeck’s eptinezumab meets endpoints in chronic migraine trial
Jun 23, 2025 • Clinical Trials Arena
Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia
Jun 23, 2025 • Morningstar.com
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Jun 21, 2025 • PR Newswire UK
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Jun 21, 2025 • Morningstar.com
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
Jun 21, 2025 • PR Newswire UK
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine
Jun 21, 2025 • Reuters
New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Jun 21, 2025 • Reuters